<div class="headers"><div>Table 1. Baseline Demographics and Clinical Characteristics of Patients.** Plus-minus values are means +SD. Analyses were performed in the safety analysis set, which included all patients who received at least one dose of tofacitinib or placebo (equivalent to the full analysis set in this trial). Unadjusted P values were determined with the use of the chi-square test for categorical variables and the Kruskal-Wallis test for continuous variables. A significant difference among trial groups was observed with respect to the mean number of tender or painful joints (unadjusted P=0.03); all other between-group differences were not significant. DMARD denotes disease-modifying antirheumatic drug, and TNF tumor necrosis factor.
■j' The data in the pooled placebo group were combined from the two groups of patients who received placebo during the first 3 months. Race was reported by the patient.
5 Scores on the Health Assessment Questionnaire-Disability Index (HAQ-DI) range from 0 to 3, with higher scores indicating greater disability. Scores on the Leeds Enthesitis Index range from 0 to 6, with higher scores indicating more affected sites. A score greater than 0 indicates the presence of enthesitis. The mean score was determined among the patients who had a score higher than 0.
II The Dactylitis Severity Score is on a scale from 0 to 60, with higher scores indicating greater severity. A score greater than 0 indicates the presence of dactylitis. The mean score was determined among the patients who had a score higher than 0.
** An elevated level of high-sensitivity C-reactive protein (CRP) was defined as a level of more than 2.87 mg per liter.
j-j- Scores on the psoriasis area-and-severity index (PASI) range 0 to 72, with higher scores indicating more severe disease. The median score was determined among patients in whom psoriasis affected at least 3% ofthe body-surface area at baseline and who had a PASI score higher than 0.
Other DMARDs included hydroxychloroquine and chloroquine.
55 The maximum permitted dose of methotrexate was 20 mg per week.
11 Norm-based scores were used for the physical functioning scores on the Medical Outcomes Study 36-ltem Short-Form Health Survey (SF-36) version 2; higher scores indicate better health-related quality of life.
Jill Scores on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) range from 0 to 52, with higher scores indicating less fatigue.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; text-align: left;'><p style="" class="">Baseline Variable</p></td>
<td style='border-top: 2px solid grey; text-align: left;'><p style="padding-left:20px; " class="indent1 ">Placebo (N = 131)i-</p></td>
<td style='border-top: 2px solid grey; text-align: left;'><p style="padding-left:20px; " class="indent1 ">Tofacitinib, 5 mg (N = 131)</p></td>
<td style='border-top: 2px solid grey; text-align: left;'><p style="padding-left:20px; " class="indent1 ">Tofacitinib, 10 mg (N = 132)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Patient demographics Age — yr</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">49.0+12.6</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">49.5+12.3</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">51.3+10.9</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Female sex— no. {%)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">80 (61)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">64 (49)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">74 (56)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">White race — no. {%)$</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">118 (90)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">121 (92)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">124 (94)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Disease characteristics Duration of psoriatic arthritis — yr</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">9.4+8.1</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">9.6+7.6</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">9.1+6.8</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">HAQ-DI scored</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">1.3+0.8</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">1.3+O.7</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">1.4+0.6</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Leeds Enthesitis Index^ Score >0 — no. {%)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">93 (71)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">83 (63)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">99 (75)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Mean score</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">2.8+1.6</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">3.0+1.6</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">3.4+1.8</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Dactylitis Severity Score) Score >0 — no. {%)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">63 (48)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">66 (50)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">65 (49)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Mean score</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">6.8+5.7</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">7.8+9.9</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">9.5+8.2</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Swollen-joint count (of 66 joints assessed) — no.</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">10.5+9.0</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">12.1+10.6</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">12.8+11.2</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Tender- or painful-joint count (of 68 joints assessed) — no.</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">19.8+14.9</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">20.5+13.0</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">25.5+17.5</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Elevated high-sensitivity CRP—no. {%)**</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">80 (61)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">85 (65)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">82 (62)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Affected body-surface area >3% — no. {%)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">86 (66)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">80 (61)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">81 (61)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Median PASI score {range)'i"i'</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">7.1 (1.6-66.0)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">7.6 (0.6-32.2)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">8.8 (0.8-41.6)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Day 1 oral glucocorticoid use — no. {%)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">31 (24)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">37 (28)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">25 (19)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Concomitant use of conventional synthetic DMARD up to 3 mo — no. {%) Methotrexate</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">101 (77)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">98 (75)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">91 (69)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Leflunomide</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">9(7)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">12(9)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">14 (11)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Sulfasalazine</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">20 (15)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">21(16)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">24 (18)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">OtherJ^:</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">1(1)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">2(2)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">1(1)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Methotrexate dose on day 1 — mg per wl<55</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">14.1+4.3</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">14.7+4.4</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">14.1+4.6</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">No. of previous TNE inhibitors</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">1.5+0.8</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">1.7+1.0</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">1.6+0.9</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Previous use of other biologic agents in addition to TNE</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">11(8)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">11(8)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">14 (11)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">inhibitors — no. {%) SE-36 physical functioning score^^</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">34.0+11.0</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">33.5+10.4</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">32.1+9.9</p></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="padding-left:20px; " class="indent1 ">EACIT-E total score) |</p></td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="padding-left:20px; " class="indent1 ">27.5+11.6</p></td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="padding-left:20px; " class="indent1 ">26.1+12.2</p></td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="padding-left:20px; " class="indent1 ">26.1+10.3</p></td>
</tr>
</tbody>
</table>
